Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted obligations through the patent life of rezafungin
 Cidara to further focus on advancing Cloudbreak development programs, including a planned IND filing for its lead oncology candidate, CBO421, as well as advancing other pipeline assets

https://www.cidara.com/news/cidara-therapeutics-announces-divestiture-of-rezafungin-to-mundipharma-to-focus-on-advancing-the-clinical-development-of-cloudbreak-dfc-pipeline